Effectiveness of Dimethyl Fumarate in Patients With Relapsing Multiple Sclerosis Switching After Suboptimal Response to Glatiramer Acetate, Including Patients With Early Multiple Sclerosis: Subgroup Analysis of RESPOND

INTRODUCTION: This post hoc subset analysis of RESPOND evaluated the effectiveness of dimethyl fumarate (DMF) 240 mg twice daily in patients with relapsing multiple sclerosis (RMS) after suboptimal response to glatiramer acetate (GA; “first switch” patients), including patients with early MS (“early...

Descripción completa

Detalles Bibliográficos
Autores principales: Repovic, Pavle, Robertson, Derrick, Kresa-Reahl, Kiren, Cohan, Stanley L., Su, Ray, Avila, Robin, Koulinska, Irene, Mendoza, Jason P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2020
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8140000/
https://www.ncbi.nlm.nih.gov/pubmed/33225410
http://dx.doi.org/10.1007/s40120-020-00223-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8140000/
https://www.ncbi.nlm.nih.gov/pubmed/33225410
http://dx.doi.org/10.1007/s40120-020-00223-2

Ejemplares similares